---
layout: default
title: Levonorgestrel
parent: 僅模型預測 (L5)
nav_order: 79
evidence_level: L5
indication_count: 6
---

# Levonorgestrel
{: .fs-9 }

證據等級: **L5** | 預測適應症: **6** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Levonorgestrel: Evaluation Report — Insufficient Data for Repurposing Assessment

## One-Sentence Summary

Levonorgestrel is a synthetic progestin primarily used in contraception (including combined oral contraceptives, progestogen-only pills, and emergency contraception).
The current Evidence Pack contains **no TxGNN model predictions** for this drug, making a drug repurposing assessment impossible at this stage.
This report documents the current data status and outlines the steps required to complete the evaluation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Contraception (not populated in Evidence Pack; based on known pharmacology) |
| Predicted New Indication | Not available — TxGNN predictions absent |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 (no predictions; data pipeline incomplete) |
| Taiwan Market Status | Not marketed (0 authorizations) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction data is present in this Evidence Pack. The `predicted_indications` array is empty, meaning either the model has not yet been run against this compound, or the results were not included in this evidence package version (v4). Without a target indication, a repurposing rationale cannot be constructed.

Levonorgestrel is a second-generation synthetic progestin (gonane class) with well-established pharmacology. Based on general pharmaceutical knowledge, it acts as a progesterone receptor agonist: inhibiting the LH surge to suppress ovulation, increasing cervical mucus viscosity, and reducing endometrial receptivity. These mechanisms intersect with several hormone-dependent conditions — including endometriosis, uterine fibroids, endometrial hyperplasia, and certain hormone-sensitive cancers — which could represent biologically plausible repurposing targets.

However, since no MOA data was retrieved from DrugBank in this run (DG002: High severity data gap), and no TxGNN predictions exist to anchor a specific new indication, any repurposing rationale at this stage would be speculative. The data pipeline must be completed before a formal assessment can proceed.

---

## Taiwan Market Information

No authorizations found in Taiwan for Levonorgestrel under the TFDA registry. The market status is confirmed as **not marketed**, with zero product listings, dosage forms, or approved indications on record.

> **Note:** The `tfda_package_insert` query returned 1 result (Query Log ID: 4). This may indicate the existence of a historical or imported product record. Retrieving and parsing this document could yield safety information and approved indication text even in the absence of active market authorizations.

---

## Safety Considerations

Please refer to the package insert for safety information.

> All safety fields (key warnings, contraindications, drug-drug interactions) are either marked as data gaps or returned no results in the current Evidence Pack. The TFDA package insert document (Query Log ID: 4, status: success) should be parsed as a priority remediation action.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is missing all three critical data categories — TxGNN predictions, mechanism of action, and safety data — making it impossible to conduct a meaningful repurposing assessment. No evaluation can proceed until the data pipeline is completed.

**To proceed, the following is needed:**

- **[Blocking]** Run TxGNN model to generate `predicted_indications` for Levonorgestrel (DB00367)
- **[Blocking]** Parse the TFDA package insert PDF (Query Log ID: 4 returned a result) to extract warnings and contraindications
- **[High]** Query DrugBank API to retrieve mechanism of action (MOA) data
- **[High]** Populate `original_indications` field from DrugBank or TFDA source data
- **[Medium]** Re-run DDI query after original indications are confirmed, to check for clinically relevant interactions
- Once predictions are available, re-generate this report using the full v4+ Evidence Pack template
## Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning.
Klinisk validering krävs före klinisk tillämpning.

---

